CSA Medical Inc.
Maryland’s CSA Medical said last week that it’s close to reaching a $4 million funding goal with a new debt offering.
CSA Medical said it raised $16 million, closing a series C financing round led by Ascension Ventures.
The Baltimore-based medical device company manufactures advanced spray cryotherapy technology that flash freezes unwanted tissue inside the body, delivering liquid nitrogen through a catheter.
Cardinal Health appointed Donald Casey Jr. to lead its $9 billion medical products and services division, effective next week.
Spinal injury therapy maker InVivo Therapeutics Holdings Corp. (OTC:NVIV) is preparing a $10 million offering, SEC filings show.
Details haven’t yet been made public regarding pricing, but the company expects to use the proceeds for research & development, working capital, capital expenditures and other general corporate purposes.
Three diabetes-related research projects at the Mayo Clinic and the University of Minnesota land more than $1.8 million in state funds in a research initiative to prevent, treat and cure diabetes.
The Minnesota Partnership for Biotechnology & Medical Genomics’ Decade of Discovery’s $1.86 million grant will fund the creation of anti-obesity drugs, explore immune-based diabetes treatments and advance the development of an artificial pancreas.
GE Healthcare (NYSE: GE) invested an undisclosed amount into C8 Medisensors, a developer of non-invasive continuous glucose monitors for diabetic patients.
C8 aims to provide glucose monitoring that is "painless, accurate, continuous, noninvasive, and nonintrusive to your life," according to its website.
The San Jose, Calif.-based company’s glucose monitors use light spectroscopy to measure blood glucose levels without the need for frequent finger pricks.
AngioDynamics Inc. (NSDQ:ANGO) named a replacement for former CEO Jan Keltjens, who left suddenly in June, tapping Joseph DeVivo for the corner office.
The Latham, N.Y.-based oncology device company also revealed the resignation of senior vice president of business development Lynda Wallace, according to SEC filings.
BALTIMORE, Sept. 12, 2011 /PRNewswire/ — CSA Medical, Inc. (www.CSAmedical.com), the leading developer of novel Spray Cryotherapy devices that flash freeze and treat diseased tissue inside the body, today announced the appointment of Wendelin Maners to the newly created position of Vice President, Emerging Therapies. In this role Maners will be responsible for the development of new therapeutic applications for the company’s Spray Cryotherapy technology.
ConforMIS Inc. is on a roll the announcement that it secured a $1.4 million loan from MassDevelopment’s Emerging Technology Fund.
The loan will go toward growing the Burlington, Mass.-based company’s supply chain and manufacturing capacity for its iTotal customized knee replacement system.